Jefferies Boosts PT on Celldex Therapeutics (CLDX) to $15

March 8, 2013 8:35 AM EST
Get Alerts CLDX Hot Sheet
Price: $3.34 -2.05%

Rating Summary:
    7 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 17 | New: 13
Trade CLDX Now!
Join SI Premium – FREE
Jefferies raised its price target on Buy-rated Celldex Therapeutics (NASDAQ: CLDX) from $9 to $15.

The firm comments, "CLDX provided an encouraging overall pipeline outlook including a risk-mitigated CDX-011 registrational strategy, and favorable rindopepimut and CDX-1135 updates. We believe CLDX represents a compelling biotech play with 2 PIII and 3 PI/II candidates providing multiple shots on goal. Our new $15 PT assumes CLDX will develop/market CDX-011 on its own, booking all U.S. sales (v royalties from a partnership previously)."

For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.

Shares of Celldex Therapeutics closed at $10.49 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment